Search

Your search keyword '"Cedrone, M."' showing total 161 results
Start Over Author "Cedrone, M."
161 results on '"Cedrone, M."'

1. Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: KENNEDY’S DISEASE AND MYELODISPLASTIC SYNDROME: A POSSIBLE NEW ENTITY IN MYELOID NEOPLASM GERMLINE PREDISPOSITION. A CASE REPORT

Author

Piccioni, A.L., primary, Fenu, S., additional, Voso, M.T., additional, Inghilleri, M., additional, Fabiani, E., additional, Panetta, P., additional, Anaclerico, B., additional, Borza, P. Anticoli, additional, Bongarzoni, V., additional, Cedrone, M., additional, Ceresoli, E., additional, Finolezzi, E., additional, Crescenzi, S. Leonetti, additional, Tamburini, A., additional, and Cudillo, L., additional

Published
2023
Full Text
View/download PDF

2. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

4. A retrospective analysis about frequency of monitoring in italian chronic myeloid leukemia patients after discontinuation

Author

Dragani, M, Cambrin, G, Berchialla, P, Dogliotti, I, Rosti, G, Castagnetti, F, Capodanno, I, Martino, B, Cerrano, M, Ferrero, D, Gambacorti Passerini, C, Crugnola, M, Elena, C, Breccia, M, Iurlo, A, Cattaneo, D, Galimberti, S, Gozzini, A, Bocchia, M, Lunghi, F, Cedrone, M, Sgherza, N, Luciano, L, Russo, S, Santoro, M, Giai, V, Caocci, G, Levato, L, Abruzzese, E, Sora, F, Saglio, G, Fava, C, Dragani M., Cambrin G. R., Berchialla P., Dogliotti I., Rosti G., Castagnetti F., Capodanno I., Martino B., Cerrano M., Ferrero D., Gambacorti Passerini C., Crugnola M., Elena C., Breccia M., Iurlo A., Cattaneo D., Galimberti S., Gozzini A., Bocchia M., Lunghi F., Cedrone M., Sgherza N., Luciano L., Russo S., Santoro M., Giai V., Caocci G., Levato L., Abruzzese E., Sora F., Saglio G., Fava C., Dragani, M, Cambrin, G, Berchialla, P, Dogliotti, I, Rosti, G, Castagnetti, F, Capodanno, I, Martino, B, Cerrano, M, Ferrero, D, Gambacorti Passerini, C, Crugnola, M, Elena, C, Breccia, M, Iurlo, A, Cattaneo, D, Galimberti, S, Gozzini, A, Bocchia, M, Lunghi, F, Cedrone, M, Sgherza, N, Luciano, L, Russo, S, Santoro, M, Giai, V, Caocci, G, Levato, L, Abruzzese, E, Sora, F, Saglio, G, Fava, C, Dragani M., Cambrin G. R., Berchialla P., Dogliotti I., Rosti G., Castagnetti F., Capodanno I., Martino B., Cerrano M., Ferrero D., Gambacorti Passerini C., Crugnola M., Elena C., Breccia M., Iurlo A., Cattaneo D., Galimberti S., Gozzini A., Bocchia M., Lunghi F., Cedrone M., Sgherza N., Luciano L., Russo S., Santoro M., Giai V., Caocci G., Levato L., Abruzzese E., Sora F., Saglio G., and Fava C.

Abstract

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported—281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months—65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.

Published
2020

5. Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Author

Fava, C, Rege-Cambrin, G, Dogliotti, I, Cerrano, M, Berchialla, P, Dragani, M, Rosti, G, Castagnetti, F, Gugliotta, G, Martino, B, Gambacorti-Passerini, C, Abruzzese, E, Elena, C, Pregno, P, Gozzini, A, Capodanno, I, Bergamaschi, M, Crugnola, M, Bocchia, M, Galimberti, S, Rapezzi, D, Iurlo, A, Cattaneo, D, Latagliata, R, Breccia, M, Cedrone, M, Santoro, M, Annunziata, M, Levato, L, Stagno, F, Cavazzini, F, Sgherza, N, Giai, V, Luciano, L, Russo, S, Musto, P, Caocci, G, Sora, F, Iuliano, F, Lunghi, F, Specchia, G, Pane, F, Ferrero, D, Baccarani, M, Saglio, G, Fava C., Rege-Cambrin G., Dogliotti I., Cerrano M., Berchialla P., Dragani M., Rosti G., Castagnetti F., Gugliotta G., Martino B., Gambacorti-Passerini C., Abruzzese E., Elena C., Pregno P., Gozzini A., Capodanno I., Bergamaschi M., Crugnola M., Bocchia M., Galimberti S., Rapezzi D., Iurlo A., Cattaneo D., Latagliata R., Breccia M., Cedrone M., Santoro M., Annunziata M., Levato L., Stagno F., Cavazzini F., Sgherza N., Giai V., Luciano L., Russo S., Musto P., Caocci G., Sora F., Iuliano F., Lunghi F., Specchia G., Pane F., Ferrero D., Baccarani M., Saglio G., Fava, C, Rege-Cambrin, G, Dogliotti, I, Cerrano, M, Berchialla, P, Dragani, M, Rosti, G, Castagnetti, F, Gugliotta, G, Martino, B, Gambacorti-Passerini, C, Abruzzese, E, Elena, C, Pregno, P, Gozzini, A, Capodanno, I, Bergamaschi, M, Crugnola, M, Bocchia, M, Galimberti, S, Rapezzi, D, Iurlo, A, Cattaneo, D, Latagliata, R, Breccia, M, Cedrone, M, Santoro, M, Annunziata, M, Levato, L, Stagno, F, Cavazzini, F, Sgherza, N, Giai, V, Luciano, L, Russo, S, Musto, P, Caocci, G, Sora, F, Iuliano, F, Lunghi, F, Specchia, G, Pane, F, Ferrero, D, Baccarani, M, Saglio, G, Fava C., Rege-Cambrin G., Dogliotti I., Cerrano M., Berchialla P., Dragani M., Rosti G., Castagnetti F., Gugliotta G., Martino B., Gambacorti-Passerini C., Abruzzese E., Elena C., Pregno P., Gozzini A., Capodanno I., Bergamaschi M., Crugnola M., Bocchia M., Galimberti S., Rapezzi D., Iurlo A., Cattaneo D., Latagliata R., Breccia M., Cedrone M., Santoro M., Annunziata M., Levato L., Stagno F., Cavazzini F., Sgherza N., Giai V., Luciano L., Russo S., Musto P., Caocci G., Sora F., Iuliano F., Lunghi F., Specchia G., Pane F., Ferrero D., Baccarani M., and Saglio G.

Abstract

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P<0.001). Eighty-eight percent of patients discontinued as per clinical practice, and reasons for stopping treatment were: toxicity (20%), pregnancy (6%), and shared decision between treating physician and patient (62%). After a median follow up of 34 months (range, 12-161) overall estimated TFR was 62% (95%CI: 56;68). At 12 months, TFR was 68% (95%CI: 62;74) for imatinib, 73% (95%CI: 64;83) for second generation TKI. Overall median time to restart treatment was six months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and second generation TKI is feasible and safe in clinical practice

Published
2019

6. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, MT., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, SF., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, AM., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, EM., Luppi, M., Marasca, R., Pogliani, EM., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, MC., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, AM., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., and DʼEmilio, A.

Published
2015
Full Text
View/download PDF

12. outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline

Author

Crugnola, M, Castagnetti, F, Breccia, M, Ferrero, D, Trawinska, Mm, Abruzzese, E, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Bonifacio, M, Fava, C, Iurlo, A, Bucelli, C, Mansueto, G, Gozzini, A, Falzetti, F, Montefusco, E, Crisà, E, Gugliotta, G, Russo, S, Cedrone, M, Russorossi, A, Pregno, P, Isidori, A, Mauro, E, Atelda, R, Giglio, G, Celesti, F, Sora', Federica, Storti, S, D'Addosio, A, Galimberti, S, Orlandi, E, Calistri, E, Bocchia, M, Cavazzini, F, Cambrin, Gr, Orofino, N, Luciano, L, Sgherza, N, Rosti, G, Latagliata, R, Capodanno, I, Sora, Federica (ORCID:0000-0002-9607-5298), Crugnola, M, Castagnetti, F, Breccia, M, Ferrero, D, Trawinska, Mm, Abruzzese, E, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Bonifacio, M, Fava, C, Iurlo, A, Bucelli, C, Mansueto, G, Gozzini, A, Falzetti, F, Montefusco, E, Crisà, E, Gugliotta, G, Russo, S, Cedrone, M, Russorossi, A, Pregno, P, Isidori, A, Mauro, E, Atelda, R, Giglio, G, Celesti, F, Sora', Federica, Storti, S, D'Addosio, A, Galimberti, S, Orlandi, E, Calistri, E, Bocchia, M, Cavazzini, F, Cambrin, Gr, Orofino, N, Luciano, L, Sgherza, N, Rosti, G, Latagliata, R, Capodanno, I, and Sora, Federica (ORCID:0000-0002-9607-5298)

Abstract

Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects

Published
2019

14. Emergency Department as an epidemiological observatory of Human Mobility: the experience of the Moroccan population

Author

Cedrone, M. C., Iaccarino, Ciro, Baldini, E., Cipollone, Lorena, Suppa, M., Bertazzoni, G, De Vito, C., Gazzaniga, V., Grasso, F., Guglielmelli, Emanuele, Iorio, S., Londei, A., Massetti, P., Migliara, G., Montanari, A., Pugliese, F. R., Ricciuto, GIULIO MARIA, Ruggieri, MARIA PIA, Susi, Beniamino, and Villari, P

Subjects
Human mobility, Emergency Department, Human mobility, Health equity, Emergency Department, Health equity
Published
2018

16. LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE

Author

Crugnola, M, Latagliata, R, Breccia, M, Ferrero, D, Trawinska, Mm, Castagnetti, F, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Fava, C, Crisa, E, Mansueto, G, Gozzini, A, Falzetti, F, Montefusco, E, Iurlo, A, Russo, S, Cedrone, M, Rossi, Ar, Gugliotta, G, Pregno, P, Isidori, A, Mauro, E, Atelda, R, Giglio, G, Celesti, F, Sora, F, Storti, S, D'Addosio, Am, Galimberti, S, Orlandi, E, Calistri, E, Bocchia, M, Cavazzini, F, Cambrin, Gr, Luciano, L, Abruzzese, E, and Capodanno, I

Published
2017

18. Observational Study of CML Italian Patients Who Discontinued TKIs

Author

Fava, C, Rege-Carmbrin, G, Dogliotti, I, Cerrano, M, Berchialla, P, Rosti, G, Castagnetti, F, Gugliotta, G, Martino, B, Gambacorti-Passerini, C, Abruzzese, E, Orlandi, Em, Elena, C, Pregno, P, Gozzini, A, Avanzini, P, Bergamaschi, M, Crugnola, M, Bocchia, M, Galimberti, S, Rapezzi, D, Iurlo, A, Cattaneo, D, Latagliata, R, Breccia, M, Cedrone, M, Santoro, M, Annunziata, M, Levato, L, Stagno, F, Cavazzini, F, Sgherza, N, Giai, V, Luciano, L, Russo, S, Musto, P, Caocci, G, Sora, F, Iuliano, F, Lunghi, F, Specchia, G, Pane, F, Baccarani, M, Ferrero, D, and Saglio, G

Published
2017

19. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms

Author

Latagliata, R, Spadea, A, Cedrone, M, Di Giandomenico, J, De Muro, M, Villiva, N, Breccia, M, Anaclerico, B, Porrini, R, Spirito, F, Rago, A, Avvisati, G, Alimena, G, Montanaro, M, Andriani, A, Volpicelli, P, Ferretti, A, Mazzucconi, M, Annino, L, Felici, S, Montefusco, E, Majolino, I, Trape, G, Pessina, G, Cotroneo, E, LO COCO, F, Abruzzese, E, and Cimino, G

Subjects
Adult, Male, Drug, Cancer Research, medicine.medical_specialty, Erythema, media_common.quotation_subject, Philadelphia Chromosome Negative, Mucocutaneous zone, Antineoplastic Agents, Partial resolution, Skin Diseases, Gastroenterology, Interquartile range, Internal medicine, Skin Ulcer, 80 and over, medicine, Humans, Hydroxyurea, Philadelphia Chromosome, Aged, media_common, Aged, 80 and over, hydroxyurea, mucocutaneous toxicity, myeloproliferative neoplasms, partial resolution, Myeloproliferative Disorders, business.industry, Cancer, Middle Aged, medicine.disease, Surgery, Withholding Treatment, Oncology, Toxicity, Female, medicine.symptom, business, Settore MED/15 - Malattie del Sangue
Abstract

BACKGROUND: The current study was conducted to evaluate severe mucocutaneous toxicity during treatment with hydroxyurea (HU) in a large cohort of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). METHODS: Among 993 consecutive patients newly diagnosed with MPN at 4 centers in Rome between January 1980 and December 2009, 614 patients (277 men and 337 women with a median age of 64.4 years [interquartile range (IR), 54.4 years-72.7 years]) received HU. HU was administered as first-line treatment in 523 patients (85.2%) and as ≥ second-line treatment in 91 patients (14.8%). RESULTS: Mucocutaneous toxicity was reported in 51 patients (8.3%) after a median period from the initiation of HU treatment of 32.1 months (IR, 10.5 months-74.6 months) and a mean HU dose of 1085 mg (± 390 mg); 30 patients (58.8%) developed a painful ulcerative skin toxicity, mainly located in the perimalleolar area; 11 patients (21.6%) had oral aphthous ulcers; and 10 patients (19.6%) developed a nonulcerative skin toxicity with erythema and skin infiltration. After the mucocutaneous toxicity occurred, HU treatment was continued at the same dose in 5 patients (9.8%), reduced in 12 patients (23.5%), and temporarily discontinued in 7 patients (13.7%); the remaining 27 patients (52.9%) required a permanent drug discontinuation. After a median period of 4.3 months (IR, 2.4 months-9.0 months) from the onset of the skin toxicity, 39 patients (76.5%) had a complete resolution and 12 patients (23.5%) had improvement without complete resolution. CONCLUSIONS: Mucocutaneous toxicity during HU treatment is more common than expected and may present with different clinical features. Moreover, it often requires a permanent drug discontinuation and only a partial resolution is reported to occur in approximately 25% of patients. Cancer 2011;. © 2011 American Cancer Society.

Published
2011

20. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

Author

Melillo, L., Tieghi, A., Candoni, A., Radaelli, F., Ciancia, R., Specchia, G., Martino, B., Scalzulli, P. R., Latagliata, R., Palmieri, F., Usala, E., Valente, D., Valvano, M. R., Cedrone, M., Comitini, G., Martinelli, V., Cascavilla, N., Gugliotta, L., Fanin, R., Iurlo, A., Zanella, A., Rotoli, B., Carluccio, P., Liso, V., Nobile, F., Santoro, C., Mazzucconi, M. G., Cantore, N., Angelucci, E., Annino, L., Cacciola, E., Cacciola, R., Giustolisi, R., Fanci, R., Bosi, A., Frungillo, N., Corradini, P., Patriarca, A., Dragani, A., De Muro, M., and Avvisati, G.

Subjects
Adult, Pediatrics, medicine.medical_specialty, Multivariate analysis, Adolescent, Alpha interferon, Abortion, Young Adult, Pregnancy, medicine, Humans, Registries, Retrospective Studies, Aspirin, Platelet Count, business.industry, Essential thrombocythemia, Obstetrics, Pregnancy Outcome, Retrospective cohort study, Hematology, Janus Kinase 2, Middle Aged, medicine.disease, Recombinant Proteins, Pregnancy Complications, Parity, Italy, Interferon Type I, Multivariate Analysis, Mutation, Gestation, Female, business, Live birth, Thrombocythemia, Essential
Abstract

Pregnancy is a high-risk event in women with essential thrombocythemia (ET). This observational study evaluated pregnancy outcome in ET patients focusing on the potential impact of aspirin (ASA) or interferon alpha (IFN) treatment during pregnancy. We retrospectively analyzed 122 pregnancies in 92 women consecutively observed in the last 10 years in 17 centers of the Italian thrombocythemia registry (RIT). The live birth rate was 75.4% (92/122 pregnancies). The risk of spontaneous abortion was 2.5-fold higher than in the control population (P < 0.01). ASA did not affect the live birth rate (71/93, 76.3% vs. 21/29, 72.4%, P = 0.67). However, IFN treatment during pregnancy was associated with a better outcome than was management without IFN (live births 19/20, 95% vs. 73/102, 71.6%, P = 0.025), and this finding was supported by multivariate analysis (OR: 0.10; 95% CI: 0.013-0.846, P = 0.034). The JAK2 V617F mutation was associated with a poorer outcome (fetal losses JAK2 V617F positive 9/25, 36% vs. wild type 2/24, 8.3%, P = 0.037), and this association was still significant after multivariate analysis (OR: 6.19; 95% CI: 1.17-32.61; P = 0.038). No outcome concordance between first and second pregnancies was found (P = 0.30). Maternal complications occurred in 8% of cases. In this retrospective study, in consecutively observed pregnant ET patients, IFN treatment was associated with a higher live birth rate, while ASA treatment was not. In addition, the JAK2 V617F mutation was confirmed to be an adverse prognostic factor.

Published
2009

21. VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?

Author

Iurlo, A, Latagliata, R, Bucelli, C, Ferrero, Dario, Castagnetti, F, Breccia, M, Abruzzese, E, Fava, Carmen, Annunziata, M, Stagno, F, Vigneri, P, Tiribelli, M, Cavazzini, F, Binotto, G, Mansueto, G, Gozzini, A, Russo, S, Falzetti, F, Montefusco, E, Gugliotta, G, Cattaneo, D, Djade, Cd, Cedrone, M, Rossi, Ar, Avanzini, P, Pregno, P, Mauro, E, Endri, M, Spadea, A, Celesti, F, Giglio, G, Isidori, A, Crugnola, M, Calistri, E, Sora, F, Sica, S, Storti, S, D'Addosio, A, Rege Cambrin, G, Luciano, L, Saglio, Giuseppe, Rosti, G, Alimena, G, Nobili, A, and Cortelezzi, A.

Published
2015

22. CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP

Author

Gugliotta, G, Castagnetti, F, Breccia, M, Stagno, F, Martino, B, Fava, Carmen, Luciano, L, Gozzini, A, Carella, Am, Abruzzese, E, Levato, L, Usala, E, Rossi, G, Bocchia, M, Tiribelli, M, Cavazzini, F, Salvucci, M, Cedrone, M, Trabacchi, E, Binotto, G, Venturi, C, Soverini, S, Cavo, M, Specchia, G, Alimena, G, Pane, F, Martinelli, G, Saglio, Giuseppe, Baccarani, M, and Rosti, G.

Subjects
Socio-culturale
Published
2015

23. ROLE OF TREATMENT ON THE DEVELOPMENT OF SECONDARY MALIGNANCIES IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA

Author

Santoro, Cristina, Sperduti, I, Di Giandomenico, J, De Muro, M, Villiva, N, Di Veroli, A, Montanaro, M, Latagliata, R, Anaclerico, B, Avvisati, G, Breccia, M, Cedrone, M, Cimino, Giuseppe, Felici, S, Ferrara, G, Crescenzi, Sl, Majolino, I, Montefusco, E, Montanaro, G, Porrini, R, Rago, A, Spadea, A, Spirito, F, Alimena, G, Andriani, A, Foa, Roberto, and Mazzucconi, Maria Gabriella

Published
2015

24. ROLE OF TREATMENT ON THE DEVELOPMENT OF SECONDARY MALIGNANCIES IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA

Author

Santoro, C., Isabella Sperduti, Di Giandomenico, J., Muro, M., Villiva, N., Di Veroli, A., Montanaro, M., Latagliata, R., Anaclerico, B., Giuseppe, A., Breccia, M., Cedrone, M., Cimino, G., Felici, S., Crescenzi, S. Leonetti, Majolino, I., Montefusco, E., Montanaro, G., Porrini, R., Rago, A., Spadea, A., Spirito, F., Alimena, G., Andriani, A., Foa, R., and Mazzucconi, M. G.

Published
2015

25. VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?

Author

Iurlo, A., Latagliata, R., Bucelli, C., Ferrero, D., Castagnetti, F., Breccia, M., Abruzzese, E., Annunziata, C. Fava M., Stagno, F., Vigneri, P., Tiribelli, M., Cavazzini, Francesco, Binotto, G., Mansueto, G., Gozzini, A., Russo, S., Falzetti, F., Montefusco, E., Gugliotta, G., Cattaneo, D., Djade, C. D., Cedrone, M., Russo Rossi, A., Avanzini, P., Pregno, P., Mauro, E., Endri, M., Spadea, A., Celesti, F., Giglio, G., Isidori, A., Crugnola, M., Calistri, E., Sorà, F., Sica, S., Storti, S., D’Addosio, A., Rege Cambrin, G., Luciano, L., Saglio, G., Rosti, G., Alimena, G., Nobili, A., and Cortelezzi, A.

Subjects
Socio-culturale
Published
2015

26. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

29. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Author

Breccia, M, Efficace, F, Sica, S, Abruzzese, E, Cedrone, M, Turri, D, Gobbi, M, Carella, A, Gozzini, A, Usala, E, Cavazzini, F, Danise, P, Tiribelli, M, Binotto, G, Pregno, P, Bocchia, M, Gaidano, G, Crugnola, M, Bonifacio, M, Avanzini, P, Celesti, F, Guella, A, Martino, B, Annunziata, M, Luciano, L, Stagno, F, Vallisa, D, Pungolino, E, Iurlo, A, Rambaldi, A, Nardiello, I, Orlandi, E, GAMBACORTI PASSERINI, C, Alimena, G, GAMBACORTI PASSERINI, CARLO, Alimena, G., Breccia, M, Efficace, F, Sica, S, Abruzzese, E, Cedrone, M, Turri, D, Gobbi, M, Carella, A, Gozzini, A, Usala, E, Cavazzini, F, Danise, P, Tiribelli, M, Binotto, G, Pregno, P, Bocchia, M, Gaidano, G, Crugnola, M, Bonifacio, M, Avanzini, P, Celesti, F, Guella, A, Martino, B, Annunziata, M, Luciano, L, Stagno, F, Vallisa, D, Pungolino, E, Iurlo, A, Rambaldi, A, Nardiello, I, Orlandi, E, GAMBACORTI PASSERINI, C, Alimena, G, GAMBACORTI PASSERINI, CARLO, and Alimena, G.

Abstract

Therapeutic approach for chronic myeloid leukemia (CML) patients has undergone a revolutionary change with the introduction of tyrosine kinase inhibitors, which improved overall survival and quality of life. Optimal therapy adherence has become of paramount importance to maximize the benefits in the long-term outcome. Several evidences have been reported that personal factors, such as social support, psychological and subjective perceptions about the drug used and the future, could influence adherence. We here report the results of a questionnaire specifically designed to evaluate factors influencing adherence and perceptions about the future, distributed to patients during regional Italian meetings. Overall, 1133 patients compiled the questionnaire: median age was 57 years. High rate of adherence was reported, but 42% of interviewed patients admitted that they had occasionally postponed a dose and 58% had discontinued therapy mainly for forgetfulness. The majority of patients discussed with personal physician about the importance of adherence and received sufficient information about illness and treatment, but would like to have discussed more about discomfort, anxiety and fear of the future. Summarizing personal drug compliance and estimating how many days a month, on average, the patients did not take the drug, the majority answered that it was less than 3 days (55%) and only a minority (4%) admitted that it was more than 7 days. Interviewed about discontinuation, 49% of patients answered that wouldn't interrupt because of fear of losing all the results achieved so far. This study suggests a higher level of satisfaction with more information received but the need of improving communication about possible future treatment free remission.

Published
2015

30. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, D'Emilio, A., Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, and D'Emilio, A.

Abstract

Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CMLWP over a 40-year period. Results: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). Conclusions: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.

Published
2015

34. NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307

Author

Rosti, G., Gugliotta, G., Breccia, M., Castagnetti, F., Levato, L., Capucci, A., Tiribelli, M., Zaccaria, A., Bocchia, M., Cuneo, A., Stagno, F., Specchia, G., Musso, M., Martino, B., Cedrone, M., Intermesoli, T., FRANCESCA PALANDRI, Soverini, S., Baldazzi, C., Durante, S., Testoni, N., Alimena, G., Pane, F., Saglio, G., Martinelli, G., Baccarani, M., G Rosti, G Gugliotta, M Breccia, F Castagnetti, L Levato, A Capucci, M Tiribelli, A Zaccaria, M Bocchia, A Cuneo, F Stagno, G Specchia, M Musso, B Martino, M Cedrone, T Intermesoli, F Palandri, S Soverini, C Baldazzi, S Durante, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, and M Baccarani

Subjects
NILOTINIB, CHRONIC MYELOID LEUKEMIA (CML)
Published
2012

36. EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS

Author

Castagnetti, F., Gugliotta, G., FRANCESCA PALANDRI, Breccia, M., Levato, L., Stagno, F., Specchia, G., Cambrin, G. Rege, Luciano, L., Gozzini, A., Martino, B., Capucci, A., Intermesoli, T., Tiribelli, M., Cedrone, M., Cavazzini, F., Usala, E., Soverini, S., Testoni, N., Pane, F., Saglio, G., Alimena, G., Martinelli, G., Rosti, G., Baccarani, M., F Castagnetti, G Gugliotta, F Palandri, M Breccia, L Levato, F Stagno, G Specchia, G Rege Cambrin, L Luciano, A Gozzini, B Martino, A Capucci, T Intermesoli, M Tiribelli, M Cedrone, F Cavazzini, E Usala, S Soverini, N Testoni, F Pane, G Saglio, G Alimena, G Martinelli, G Rosti, and M Baccarani.

Subjects
NILOTINIB, CHRONIC MYELOID LEUKEMIA (CML)
Published
2012

39. A RETROSPECTIVE ANALYSIS OF 990 PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA(ET) FOLLOWED IN THE LAZIO REGION FROM 1979 TO DATE: DEFINITION OF PROGNOSTIC FACTORS ON THROMBOSIS-FREE SURVIVAL (TFS) AND OVERALL SURVIVAL (OS)

Author

Montanaro, M, Latagliata R, Cedrone, M, Spirito, F, Ruscio, C, Leonetti Crescenzi, S, Porrini, R, Di Giandomenico, J, Cotroneo, E, Villivà, N, Spadea, A, Rago, A, De Gregoris, C, Pessina, G, Di Muro, M, Felici, S, Breccia, M, Montefusco, E, Bagnato, A, Annino, L, Cimino, G, Majolino, I, Alimena, G, and Andriani, A

Published
2011

40. Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the 'Gruppo Laziale SMPC Ph Negative

Author

Montanaro, M., Latagliata, R., Cedrone, M., Villiva, N., Porrini, R., Spirito, F., Rago, Angela, Crescenzi Sl, Spadea A., De Muro, M., Cotroneo, E., Breccia, M., De Gregoris, C., Anaclerico, B., Felici, S., Ruscio, C., Di Giandomenico, J., Franceschini, L., Pessina, G., Cimino, Giuseppe, Montefusco, E., Majolino, I., Mazzucconi, Maria Gabriella, Alimena, Giuliana, and Andriani, A.

Published
2011

41. LOW-DOSE IMATINIB IN VERY ELDERLY (> 75 YEARS) CML PATIENTS: IS IT ENOUGH?

Author

Latagliata, R, Ferrero, D, Cavazzini, F, Trawinska, M, Breccia, M, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Crisà, E, Musto, P, Gozzini, A, Cavalli, L, Porrini, R, Iurlo, A, Musolino, C, Cedrone, M, Russo Rossi, A, Pregno, P, Endri, M, Spadea, A, Giglio, G, Celesti, F, Sorà, F, Gasbarrino, C, D’Addosio, A, Rege Cambrin, G, Luciano, L, Abruzzese, E, and Alimena, G

Published
2011

42. A RETROSPECTIVE ANALYSIS OF 603 PATIENTS WITH POLYCYTHEMIA VERA (PV) FOLLOWED IN THE LAZIO REGION FROM 1979 TO DATE: DEFINITION OF PROGNOSTIC FACTORS ON THROMBOSIS-FREE SURVIVAL (TFS) AND OVERALL SURVIVAL (OS)

Author

Andriani, A, Latagliata R, Cedrone, M, Spirito, F, Ruscio, C, Leonetti Crescenzi, S, Porrini, R, Di Giandomenico, J, Cotroneo, E, Villivà, N, Spadea, A, Rago, A, De Gregoris, C, Pessina, G, Di Muro, M, Felici, S, Breccia, M, Montefusco, E, Bagnato, A, Annino, L, Cimino, G, Majolino, I, Alimena, G, and Montanaro, M

Published
2011

43. Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?

Author

Latagliata, R., Breccia, M., Ferrero, D., Cavazzini, Francesco, Trawinska, M. M., Castagnetti, F., Annunziata, M., Stagno, F., Tiribelli, M., Imbergamo, S., Fava, C., Crisà, E., Pietrantuono, G., Gozzini, A., Falzetti, F., Montefusco, E., Iurlo, A., Musolino, C., Cedrone, M., Russo Rossi, A., Pregno, P., Visani, G., Capodanno, I., Mauro, E., Spadea, A., Giglio, G., Celesti, F., Sica, S., Storti, S., D'Addosio, A. M., Rege Cambrin, G., Luciano, L., Abruzzese, E., Rosti, G., and Alimena, G.

Published
2011

47. IMPROVING ON IMATINIB FOR TARGETED THERAPY OF CHRONIC MYELOID LEUKEMIA: FIRST LINE TREATMENT WITH NILOTINIB 800 MG DAILY RESULTS IN UNPRECEDENTEDLY HIGH RATE OF RAPID, 'DEEP' AND STABLE MOLECULAR RESPONSES - RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY

Author

Martinelli, G, Poerio, A, Soverini, S, Saglio, G, Pane, F, Castagnetti, F, Capucci, A, Tiribelli, M, Stagno, F, Palandri, F, Gugliotta, G, Zaccaria, A, Intermesoli, T, Martino, B, Bocchia, M, Cedrone, M, Testoni, N, Amabile, M, Iacobucci, I, Breccia, M, Alimena, G, Levato, L, Baccarani, M, and Rosti, G

Published
2010

48. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Author

Breccia, M, Luciano, L, Latagliata, R, Castagnetti, F, Ferrero, D, Cavazzini, F, Trawinska, Mm, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Crisà, E, Musto, P, Gozzini, A, Cavalli, L, Montefusco, E, Iurlo, A, Russo, S, Cedrone, M, Rossi, Ar, Pregno, P, Endri, M, Spadea, A, Molica, M, Giglio, G, Celesti, F, Sora', Federica, Storti, Sergio, D'Addosio, A, Cambrin, Gr, Isidori, A, Sica, Simona, Abruzzese, E, Speccha, G, Rosti, G, Alimena, G., Sora', Federica (ORCID:0000-0002-9607-5298), Storti, S (ORCID:0000-0002-4374-3985), Sica, Simona (ORCID:0000-0003-2426-3465), Breccia, M, Luciano, L, Latagliata, R, Castagnetti, F, Ferrero, D, Cavazzini, F, Trawinska, Mm, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Crisà, E, Musto, P, Gozzini, A, Cavalli, L, Montefusco, E, Iurlo, A, Russo, S, Cedrone, M, Rossi, Ar, Pregno, P, Endri, M, Spadea, A, Molica, M, Giglio, G, Celesti, F, Sora', Federica, Storti, Sergio, D'Addosio, A, Cambrin, Gr, Isidori, A, Sica, Simona, Abruzzese, E, Speccha, G, Rosti, G, Alimena, G., Sora', Federica (ORCID:0000-0002-9607-5298), Storti, S (ORCID:0000-0002-4374-3985), and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

We applied Charlson comorbidity index (CCI) stratification on a large cohort of chronic myeloid leukemia (CML) very elderly patients (>75 years) treated with imatinib, in order to observe the impact of concomitant diseases on both compliance and outcome. One hundred and eighty-one patients were recruited by 21 Italian centers. There were 95 males and 86 females, median age 78.6 years (range 75-93.6). According to Sokal score, 106 patients were classified as intermediate risk and 55 as high risk (not available in 20 patients). According to CCI stratification, 71 patients had score 0 and 110 a score ≥ 1. Imatinib standard dose was reduced at start of therapy (200-300 mg/day) in 68 patients independently from the evaluation of baseline comorbidities, but based only on physician judgement: 43.6% of these patients had score 0 compared to 34% of patients who had score ≥ 1. Significant differences were found in terms of subsequent dose reduction (39% of patients with score 0 compared to 53% of patients with score ≥ 1) and in terms of drug discontinuation due to toxicity (35% of patients with score 0 vs 65% of patients with score ≥ 1). We did not find significant differences as regards occurrence of hematologic side effects, probably as a consequence of the initial dose reduction: 39% of patients with score 0 experienced grade 3/4 hematologic toxicity (most commonly anemia) compared to 42% of patients with score ≥ 1. Independently from the initial dose, comorbidities again did not have an impact on development of grade 3/4 non-hematologic side effects (most commonly skin rash, muscle cramps and fluid retention): 62% of patients with score 0 compared to 52.5% of patients with score ≥ 1. Notwithstanding the reduced dose and the weight of comorbidities we did not find significant differences but only a trend in terms of efficacy: 66% of patients with score 0 achieved a CCyR compared to 54% of patients with score ≥ 1. Comorbidities appeared to have an impact on median OS (40.8

Published
2014

49. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

Author

Latagliata, R, Ferrero, D, Iurlo, A, Cavazzini, F, Castagnetti, F, Abruzzese, E, Fava, C, Breccia, M, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Mansueto, G, Gozzini, A, Russo, S, Cavalli, L, Montefusco, E, Gugliotta, G, Cedrone, M, Russo Rossi, A, Avanzini, P, Pregno, P, Mauro, E, Spadea, A, Celesti, F, Giglio, G, Isidori, A, Crugnola, M, Calistri, E, Sora', Federica, D'Addosio, A, Rege Cambrin, G, Luciano, L, Alimena, G., Storti, S, Sora', Federica (ORCID:0000-0002-9607-5298), Latagliata, R, Ferrero, D, Iurlo, A, Cavazzini, F, Castagnetti, F, Abruzzese, E, Fava, C, Breccia, M, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Mansueto, G, Gozzini, A, Russo, S, Cavalli, L, Montefusco, E, Gugliotta, G, Cedrone, M, Russo Rossi, A, Avanzini, P, Pregno, P, Mauro, E, Spadea, A, Celesti, F, Giglio, G, Isidori, A, Crugnola, M, Calistri, E, Sora', Federica, D'Addosio, A, Rege Cambrin, G, Luciano, L, Alimena, G., Storti, S, and Sora', Federica (ORCID:0000-0002-9607-5298)

Abstract

A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results